Merck's Enflonsia vaccine for respiratory syncytial virus won approval from the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices.

The Centers for Disease Control and Prevention's vaccine advisory committee wrapped up the first day of its meeting since Health and Human Services Secretary Robert F. Kennedy Jr. dismissed the entire panel and appointed his own hand-selected members.

A group of outside advisers to the US Centers for Disease Control and Prevention voted 5-2 to recommend use of a new shot that can protect babies from respiratory syncytial virus, adding an additional tool against the most common cause of hospitalization in infants.